Skip to content

Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)

Enhancing the Cardiovascular Safety of Hemodialysis Care: A Cluster-Randomized, Comparative Effectiveness Trial of Multimodal Provider Education and Patient Activation Interventions (Dialysafe)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03171545
Acronym
Dialysafe
Enrollment
1431
Registered
2017-05-31
Start date
2023-01-11
Completion date
2024-12-13
Last updated
2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Failure, End Stage Renal Disease, Hypotension, Cardiovascular Diseases, Patient Safety

Keywords

Peer Mentoring, Team Training, Checklist

Brief summary

The purpose of this study is reduce episodes of intradialytic hypotension, low blood pressure during a hemodialysis session, in patients with End Stage Renal Disease (ESRD). Recruitment will take place on the clinic level rather than the patient level.

Detailed description

When a person's kidneys stop working, he or she has end-stage renal disease (ESRD). Individuals with ESRD cannot live without either dialysis therapy-in which a machine performs the functions of the kidneys-or a kidney transplant. Dialysis must remove fluid as well as toxins in the blood. People with ESRD have a high risk for death, and the usual cause is cardiovascular disease. Most people in the United States who have ESRD get hemodialysis therapy in a clinic for four hours at a time, three times a week. The stability of hemodialysis sessions varies, and many sessions become unstable from low blood pressure and other complications. Unstable dialysis sessions can result in negative symptoms, like fatigue. Dialysis instability is an important problem. Session instability is linked to injury to the heart and other organs. Patients who have unstable dialysis sessions are more likely to end up in the hospital or die than are those who have stable sessions. Session instability is preventable. The main causes of instability are removal of fluid from a patient too fast or removal of too much fluid. Session instability results from many factors: decisions made by patients, and decisions by healthcare providers. Presently, the way to best improve the stability of dialysis is not clear. Dialysis clinics approach this problem differently, and there is variation among clinics in how often hemodialysis sessions become unstable. In partnership with the National Kidney Foundation and Fresenius Medical Care North America, the investigators will test two interventions designed to increase the stability of patient dialysis. One intervention, multimodal provider education, focuses on dialysis facility care teams. It includes team training, online education, and a checklist. Another intervention, patient activation, focuses on patients. It includes peer mentoring by trained ESRD patients. Mentors will hold with other patients multimedia-aided meetings that include skills instruction and role modeling. These interventions have been successful in hospital care and in chronic disease care, and the investigators will adapt them to dialysis safety. The investigators will then conduct a study in 20 dialysis facilities in different parts of the United States. Five facilities will get the provider education only; five will get the patient activation intervention only; five will get both interventions; and five will get no interventions. The investigators will test whether session stability improves in the facilities that get either intervention over the 48-week study period. This study is expected to clarify whether these interventions can make dialysis safer for ESRD patients. This will inform hemodialysis care providers on whether to pursue provider-focused or patient-focused safety interventions, or both. People on hemodialysis will also have information to help them decide whether to become engaged in their session stability, and the intervention will help them learn how to do so.

Interventions

BEHAVIORALPatient Activation

Patients in clinics assigned to this group will be offered peer mentoring and digital resources.

Staff in clinics assigned to this group will receive team training and a checklist.

Sponsors

University of California, Irvine
CollaboratorOTHER
National Kidney Foundation, United States
CollaboratorOTHER
Fresenius Medical Care North America
CollaboratorINDUSTRY
University of Michigan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

The study is a 2X2 factorial design, such that five facilities will get the provider education only; five will get the patient activation intervention only; five will get both interventions; and five will get no interventions.

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Selection is at both the clinic level and individual patient level. Clinic Inclusion Criteria: * outpatient hemodialysis facilities * at least 70 adult (\>21 years old) patients to guarantee sample size Clinic

Exclusion criteria

* facilities involved in another study * facilities in immediate jeopardy * facilities with 1-star quality ratings * facilities designated as COVID-19 isolation facilities Individual Patient

Design outcomes

Primary

MeasureTime frameDescription
Dialysis Session Stability24 weeksSystolic blood pressure (SBP) falling below 100 mmHg (using lowest SBP during session) if starting SBP ≥100.

Secondary

MeasureTime frameDescription
Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period24 weeksMeasured as the average number of minutes of prescribed dialysis time missed per week during intervention period (number of prescribed minutes-number of actual minutes/24 week intervention period).
Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period24 weeksMeasured as the average number of missed sessions per week during the intervention period (number of prescribed sessions-number of actual sessions/24 week intervention period).
Patient Symptoms - Post-dialysis Recovery Time24 weeksMeasured at midweek session as patient recovery time after dialysis, reported on a survey item on an ordinal scale from within minutes to did not recover before the next scheduled dialysis session. Responses grouped into three categories for analysis: did not recover, recovered before reaching home, and recovered on same day of treatment. Sessions categorized as recovered before reaching home used for comparison between study arms.
Patient Symptoms - Symptom Burden24 weeksMeasured as the total number symptoms reported by the patient at each session (each symptom treated as one, then added to create total symptoms).
Fluid Adherence24 weeksMeasured by interdialytic weight gain (in Kilograms), which is the weight gained between dialysis sessions (presented as average throughout 24 week intervention period)
Quality of Life-KDQOL - PCSpost-intervention surveyTotal score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). PCS (physical component summary) ranges from 7.3 - 70.1; higher scores represent better functioning.
Hospitalization24 weeksHospitalization rates, measured as a total number of hospital admission for any reason per total patients year (all-cause hospitalizations)
Mortality24 weeksMortality rates, measured as a total number of deaths due to any cause per 100 patient years during the study period (all-cause mortality).
Quality of Life-KDQOL - MCSpost-intervention surveyTotal score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). MCS (mental component summary) subscale ranges from 5.8 - 69.9; higher scores represent better functioning.

Countries

United States

Participant flow

Participants by arm

ArmCount
No Intervention
Patients in clinic receive usual care.
382
Patient Activation
This arm focuses on patients. It includes peer mentoring by trained End Stage Renal Disease (ESRD) patients. Mentors will hold 5 multimedia-aided meetings with other patients that include motivational interviewing and role modeling.
346
Provider Education
This arm focuses on dialysis facility care teams. It includes team training, online education, and checklists.
410
Patient and Provider
This arm includes both Patient Activation and Provider Education interventions
293
Total1,431

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
BaselineDeath1215
BaselineNo longer receiving in-center hemodialysis0230
BaselineReceived transplant0010
BaselineRecovered renal function0010
BaselineTransferred out of clinic4020
BaselineWithdrawal by Subject0012
Follow upDeath181258
Follow upLost to Follow-up1231
Follow upNo longer receiving in-center hemodialysis4210
Follow upReceived transplant4101
Follow upTransferred out of clinic44127
Follow upWithdrawal by Subject1100
InterventionDeath26162914
InterventionLost to Follow-up0100
InterventionNo longer receiving in-center hemodialysis7446
InterventionReceived transplant7536
InterventionTransferred out of clinic129179
InterventionWithdrawal by Subject2004

Baseline characteristics

CharacteristicNo InterventionTotalPatient and ProviderProvider EducationPatient Activation
Age, Continuous65.45 years
STANDARD_DEVIATION 13.92
62.63 years
STANDARD_DEVIATION 14.27
61.66 years
STANDARD_DEVIATION 14.7
59.90 years
STANDARD_DEVIATION 13.36
63.58 years
STANDARD_DEVIATION 14.72
Dialysis Session Stability0.197 Proportion of sessions
STANDARD_DEVIATION 0.215
0.187 Proportion of sessions
STANDARD_DEVIATION 0.212
0.177 Proportion of sessions
STANDARD_DEVIATION 0.213
0.175 Proportion of sessions
STANDARD_DEVIATION 0.206
0.198 Proportion of sessions
STANDARD_DEVIATION 0.212
Ethnicity (NIH/OMB)
Hispanic or Latino
71 Participants209 Participants32 Participants38 Participants68 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
307 Participants1170 Participants245 Participants353 Participants265 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants52 Participants16 Participants19 Participants13 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants2 Participants0 Participants1 Participants0 Participants
Race (NIH/OMB)
Asian
6 Participants24 Participants3 Participants9 Participants6 Participants
Race (NIH/OMB)
Black or African American
115 Participants569 Participants130 Participants233 Participants91 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
3 Participants5 Participants0 Participants0 Participants2 Participants
Race (NIH/OMB)
Unknown or Not Reported
5 Participants42 Participants13 Participants10 Participants14 Participants
Race (NIH/OMB)
White
252 Participants789 Participants147 Participants157 Participants233 Participants
Sex: Female, Male
Female
163 Participants594 Participants115 Participants162 Participants154 Participants
Sex: Female, Male
Male
219 Participants837 Participants178 Participants248 Participants192 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
45 / 38230 / 34635 / 41027 / 293
other
Total, other adverse events
0 / 3820 / 3460 / 4100 / 293
serious
Total, serious adverse events
0 / 3820 / 3460 / 4100 / 293

Outcome results

Primary

Dialysis Session Stability

Systolic blood pressure (SBP) falling below 100 mmHg (using lowest SBP during session) if starting SBP ≥100.

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionDialysis Session Stability0.202 Proportion of sessionsStandard Deviation 0.217
Patient ActivationDialysis Session Stability0.199 Proportion of sessionsStandard Deviation 0.204
Provider EducationDialysis Session Stability0.172 Proportion of sessionsStandard Deviation 0.19
Patient and ProviderDialysis Session Stability0.182 Proportion of sessionsStandard Deviation 0.205
Secondary

Dialysis Adherence - Average Weekly Minutes Missed Over Intervention Period

Measured as the average number of minutes of prescribed dialysis time missed per week during intervention period (number of prescribed minutes-number of actual minutes/24 week intervention period).

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionDialysis Adherence - Average Weekly Minutes Missed Over Intervention Period5.23 average weekly minutesStandard Deviation 13.48
Patient ActivationDialysis Adherence - Average Weekly Minutes Missed Over Intervention Period4.21 average weekly minutesStandard Deviation 9.05
Provider EducationDialysis Adherence - Average Weekly Minutes Missed Over Intervention Period5.28 average weekly minutesStandard Deviation 10.58
Patient and ProviderDialysis Adherence - Average Weekly Minutes Missed Over Intervention Period4.89 average weekly minutesStandard Deviation 11.69
Secondary

Dialysis Adherence - Average Weekly Sessions Missed During Intervention Period

Measured as the average number of missed sessions per week during the intervention period (number of prescribed sessions-number of actual sessions/24 week intervention period).

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionDialysis Adherence - Average Weekly Sessions Missed During Intervention Period0.004 average proportion of sessions missedStandard Deviation 0.008
Patient ActivationDialysis Adherence - Average Weekly Sessions Missed During Intervention Period0.008 average proportion of sessions missedStandard Deviation 0.041
Provider EducationDialysis Adherence - Average Weekly Sessions Missed During Intervention Period0.028 average proportion of sessions missedStandard Deviation 0.061
Patient and ProviderDialysis Adherence - Average Weekly Sessions Missed During Intervention Period0.032 average proportion of sessions missedStandard Deviation 0.077
Secondary

Fluid Adherence

Measured by interdialytic weight gain (in Kilograms), which is the weight gained between dialysis sessions (presented as average throughout 24 week intervention period)

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionFluid Adherence2.12 KgStandard Deviation 0.87
Patient ActivationFluid Adherence2.18 KgStandard Deviation 1.18
Provider EducationFluid Adherence2.35 KgStandard Deviation 0.93
Patient and ProviderFluid Adherence2.34 KgStandard Deviation 1.01
Secondary

Hospitalization

Hospitalization rates, measured as a total number of hospital admission for any reason per total patients year (all-cause hospitalizations)

Time frame: 24 weeks

ArmMeasureValue (NUMBER)
No InterventionHospitalization1.55 hospitalizations per patient year
Patient ActivationHospitalization1.15 hospitalizations per patient year
Provider EducationHospitalization1.37 hospitalizations per patient year
Patient and ProviderHospitalization1.23 hospitalizations per patient year
Secondary

Mortality

Mortality rates, measured as a total number of deaths due to any cause per 100 patient years during the study period (all-cause mortality).

Time frame: 24 weeks

ArmMeasureValue (NUMBER)
No InterventionMortality16.99 Deaths per 100 patient years
Patient ActivationMortality9.30 Deaths per 100 patient years
Provider EducationMortality14.85 Deaths per 100 patient years
Patient and ProviderMortality10.44 Deaths per 100 patient years
Secondary

Patient Symptoms - Post-dialysis Recovery Time

Measured at midweek session as patient recovery time after dialysis, reported on a survey item on an ordinal scale from within minutes to did not recover before the next scheduled dialysis session. Responses grouped into three categories for analysis: did not recover, recovered before reaching home, and recovered on same day of treatment. Sessions categorized as recovered before reaching home used for comparison between study arms.

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionPatient Symptoms - Post-dialysis Recovery Time0.141 Proportion session recovery before homeStandard Deviation 0.106
Patient ActivationPatient Symptoms - Post-dialysis Recovery Time0.181 Proportion session recovery before homeStandard Deviation 0.091
Provider EducationPatient Symptoms - Post-dialysis Recovery Time0.178 Proportion session recovery before homeStandard Deviation 0.091
Patient and ProviderPatient Symptoms - Post-dialysis Recovery Time0.158 Proportion session recovery before homeStandard Deviation 0.108
Secondary

Patient Symptoms - Symptom Burden

Measured as the total number symptoms reported by the patient at each session (each symptom treated as one, then added to create total symptoms).

Time frame: 24 weeks

ArmMeasureValue (MEAN)Dispersion
No InterventionPatient Symptoms - Symptom Burden0.045 Average symptoms reported per sessionStandard Deviation 0.095
Patient ActivationPatient Symptoms - Symptom Burden0.069 Average symptoms reported per sessionStandard Deviation 0.154
Provider EducationPatient Symptoms - Symptom Burden0.051 Average symptoms reported per sessionStandard Deviation 0.123
Patient and ProviderPatient Symptoms - Symptom Burden0.063 Average symptoms reported per sessionStandard Deviation 0.133
Secondary

Quality of Life-KDQOL - MCS

Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). MCS (mental component summary) subscale ranges from 5.8 - 69.9; higher scores represent better functioning.

Time frame: post-intervention survey

ArmMeasureValue (MEAN)Dispersion
No InterventionQuality of Life-KDQOL - MCS53.85 ScoreStandard Deviation 8.73
Patient ActivationQuality of Life-KDQOL - MCS52.62 ScoreStandard Deviation 10.16
Provider EducationQuality of Life-KDQOL - MCS54.58 ScoreStandard Deviation 8.3
Patient and ProviderQuality of Life-KDQOL - MCS54.89 ScoreStandard Deviation 8.67
Secondary

Quality of Life-KDQOL - PCS

Total score measured by adding responses on the Kidney Disease Quality of Life survey (KDQOLTM-36 Version 1). PCS (physical component summary) ranges from 7.3 - 70.1; higher scores represent better functioning.

Time frame: post-intervention survey

ArmMeasureValue (MEAN)Dispersion
No InterventionQuality of Life-KDQOL - PCS35.98 ScoreStandard Deviation 10.05
Patient ActivationQuality of Life-KDQOL - PCS38.01 ScoreStandard Deviation 10.36
Provider EducationQuality of Life-KDQOL - PCS39.49 ScoreStandard Deviation 11.7
Patient and ProviderQuality of Life-KDQOL - PCS36.18 ScoreStandard Deviation 10.99

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026